Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year

Table 4 Clinical and functional status at one-year follow-up by APR levels among biologic-naïve patients

	Neither APR elevated	APR levels discordant	Both APR elevated	P value
	n = 1,012	n = 487	n = 324
mHAQ	0.28 ± 0.40	0.32 ± 0.43	0.34 ± 0.46	0.0623
CDAI	9.65 ± 10.11	9.75 ± 9.81	10.85 ± 11.17	0.2243
Tender joints	2.64 ± 4.93	2.41 ± 4.33	2.83 ± 5.17	0.4378*
Swollen joints	2.90 ± 4.66	2.91 ± 4.54	3.52 ± 5.04	0.1299*
Patient global assessment	26.23 ± 24.77	28.36 ± 25.62	28.68 ± 26.53	0.1149
MD global assessment	14.52 ± 14.82	15.61 ± 15.38	16.43 ± 15.85	<0.0001
Biologic use	150 (14.84%)	83 (17.08%)	67 (20.68%)	0.0437

^*Log-linear model (Poisson) - χ² test. APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.

ISSN: 1478-6362